Drug Profile
Vosaroxin - Denovo Biopharma/Sumitomo Pharma
Alternative Names: AG-7352; AG-7352 hydrochloride; DB 106; QINPREZO; SNS-595; SPC-595; VoreloxinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Cardiff University; Sunesis Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Viracta Therapeutics; Washington University School of Medicine; Weill Cornell Medical College
- Class Antineoplastics; Carboxylic acids; Naphthyridines; Pyrrolidines; Quinolones; Small molecules; Thiazoles
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia
- Phase II/III Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma
- No development reported Glioblastoma
- Discontinued Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
Most Recent Events
- 02 Jan 2023 Vosaroxin is still in phase-II/III trials for Precursor B-cell lymphoblastic leukaemia-lymphoma in Denmark (IV)(EudraCT2011-000749-19)
- 02 Jan 2023 No development reported - Phase-II for Acute myeloid leukaemia (Combination therapy, In the elderly, Newly diagnosed) in Germany (IV) (Denovo Biopharma pipeline; January 2022).
- 02 Jan 2023 No development reported - Phase-II for Myelodysplastic syndromes (Combination therapy, In the elderly, Second-line therapy or greater) in Germany (IV) (Denovo Biopharma pipeline; January 2022)